Category Archives: Chưa được phân loại

The research team at the National Children’s Hospital and the Spobiotic Research Center of ANABIO R&D has published impressive results on the effectiveness of liquid Bacillus clausii spores (LiveSpo CLAUSY, Bacillus clausii concentration ≥ 2 billion/5 mL vial) in supporting the treatment of prolonged diarrhea in children.

This clinical trial marks a significant advancement in understanding and treating pediatric diarrhea. The probiotic product LiveSpo CLAUSY is not only safe for children but also shortens the treatment duration by 2-3 days and enhances effectiveness by up to 50-60%, depending on specific symptoms. Notably, the product can reduce the excessive secretion of pro-inflammatory cytokines by up to 29%, a key factor in reducing inflammation and restoring the intestinal mucosa.

This breakthrough brings new hope for children suffering from prolonged diarrhea and opens up promising prospects for research and treatment of other gastrointestinal diseases.

On August 11, 2024, the 2nd International Conference on Microbiology and One Health (MOH-VN 2024) took place at the International Centre for Interdisciplinary Science and Education (ICISE) in Quy Nhon, Binh Dinh. The conference attracted nearly 140 speakers, scientists, and doctors from 25 countries and territories.

The Spobio Research Center – ANABIO R&D Co., Ltd. sent two representatives to attend the conference and present a report on “Bacillus Spore Probiotics: Enhancing Diarrhea Treatment in Children while Reducing Antibiotic ependence by Regulating Immune Responses and Restoring Gut Microbiota.” The report received significant attention and appreciation from many of the attendees.

At the conference, scientists and researchers engaged in in-depth discussions about the “One Health” model, a holistic approach that links human health closely with overall environmental health. They aimed to develop new research directions and seek comprehensive solutions to protect public health. The conference also served as a platform for networking, knowledge exchange, and generating new ideas for “a future without antibiotics.”

Below are some images from the conference:

On September 15, 2022, the ETC department and ANABIO R&D had a meeting to share at the Department of Pediatrics – Thai Nguyen Central General Hospital about a set of 03 products: LiveSpo Navax, LiveSpo Dia30 and LiveSpo Pregmon

At the meeting, the research team of ANABIO R&D brought expertise and basic information about LiveSpo Navax, LiveSpo Dia30 and LiveSpo Pregmon products as well as answered common problems encountered during the adjustment process. treatment, used when combining products. This helps to strengthen and create trust for the team of doctors and customers during use.

On July 20th, 2022, the research article regarding nasal-spraying spore probiotics LiveSpo Navax entitled “Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection” was published in Scientific Reports-Nature, the prestigious international scientific journal. The study was conducted in collaboration between LiveSpo Pharma Co. Ltd., and researchers at Vietnam National Children’s Hospital.

Scientific Reports, belonging to Nature system, is famous medical journal in the world. By the publication on effects of spore probiotics originating from Vietnam, Dr. Nguyen Hoa Anh – Director of ANABIO R&D Co. Ltd., expects to be able to contribute to the field of science and public health care, especially children.

The research group conducted the clinical trial of nasal-spraying spore probiotics LiveSpo Navax on RSV infected children. LiveSpo Navax is ear, nose and throat cleaning solution containing more than 5 billion of spore probiotics Bacillus subtilis and Bacillus clausii and physiological saline solution (NaCl 0.9%) in sufficient 5 mL. Product is dedicated for cleaning of ear, nose and throat; help preventing and reducing the risk of ear, nose and throat infections; supplementing of spore probiotics to protect and recover the nasal mucosa.

The study demonstrates that LiveSpo Navax treatment resulted in 1-day faster recovery time and 10-50% better efficacy in relieving typical symptoms of acute respiratory tract infections (ARTIs) in comparison to control group. At day 3 of treatment, levels of RSV load and pro-inflammatory cytokines in nasopharyngeal samples of patients using LiveSpo Navax were remarkably reduced by 630 folds and 2.7-12.7 folds, respectively, which was 53-fold and 1.8 to 3.6-fold more effective than those in standard of care treatment.

Spraying LiveSpo Navax directly in to nasal cavity helps reducing the symptoms of ARTIs rapidly. In combination between LiveSpo Navax and standard therapy, the recovery time is shortened by 1 day (17%) with 10-50% more effectiveness in relieving typical symptom of ARTIs than physiological saline solution. Most of patients having positive co-infection bacteria in Navax group became negative after 3 days of treatment, while low reduction and even increment in co-infection bacteria were detected in most of patients in standard of care treatment.

Dr, Nguyen Hoa Anh, a member of research group and Director of ANABIO R&D, said: The mechanism of interaction between spore probiotic Bacillus in LiveSpo Navax and virus and immune system of nasal mucosa is based on non-specific interaction. “Our discovery suggests that LiveSpo Navax may useful for against the recent novel respiratory viral variants such as nCoV. This novel supportive treatment method using probiotics has the advantage of simplicity of use, low cost, effectible and viral infected prevention. It can support the developing countries with limited health resources”.